Gout is not simply a series of isolated painful attacks. It is a crystal-deposition disease that can progress over time when serum urate remains high enough for monosodium urate crystals to form and persist. The stages make more sense alongside high uric acid vs. gout, recurrent gout flares and tophi and tophaceous gout.
The exact course differs from person to person, but clinicians commonly describe gout in four broad stages.
1. Asymptomatic hyperuricemia
Serum urate is elevated, but there have been no gout flares or tophi. Many people with high urate never develop gout, so an elevated number alone does not equal a gout diagnosis. Risk depends on factors including genetics, kidney function, medications, body weight and how high the urate level is over time.
2. An acute gout flare
A flare is the sudden inflammatory response to urate crystals in a joint. Pain, redness, warmth and swelling often develop rapidly, commonly overnight. The big toe is classic, but ankles, knees, wrists, fingers and other joints can be affected.
A first red, hot, swollen joint should be medically assessed because infection and other forms of arthritis can resemble gout.
3. Intercritical gout
This is the symptom-free period between attacks. Feeling normal does not necessarily mean the gout has disappeared. Urate crystals can remain in joints and tissues even when there is no pain. Without effective urate control, flares may recur and may become more frequent.
4. Chronic tophaceous or advanced gout
Over years of uncontrolled hyperuricemia, larger deposits called tophi may develop around joints, tendons or soft tissues. Chronic inflammation and erosive joint damage can occur. The good news is that urate deposits can shrink and sometimes disappear when serum urate is kept below target long enough.
Can progression be stopped?
Yes. Modern gout care aims to control flares and, when urate-lowering therapy is indicated, keep serum urate below target so existing crystals gradually dissolve. NICE recommends a target below 6 mg/dL (360 micromol/L), with a lower target below 5 mg/dL (300 micromol/L) considered for people with tophi, chronic gouty arthritis or ongoing frequent flares.
Different health systems use slightly different treatment pathways, but the central biology is the same. The American College of Rheumatology, NICE in the UK and Australian rheumatology resources all emphasize sustained urate lowering for long-term disease control.
This article is educational and is not a substitute for individualized medical care.
Sources
- NICE NG219: Gout—diagnosis and management
- American College of Rheumatology: 2020 Gout Guideline
- Arthritis Australia: What about gout?
- Kenya Ministry of Health: Clinical Guidelines 2024
Evidence checked September 2026.